Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | BCL3 | P20749 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678080 | 0.86 | LMNA (0.79) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL17706285 | 0.86 | KMT2A (0.68) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL17706243 | 0.86 | KMT2A (0.65) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL17706244 | 0.86 | KMT2A (0.65) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL14756465 | 0.84 | KMT2A (0.63) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL6109276 | 0.83 | LMNA (0.74) | KMT2AALDH1A1LMNASMN1; SMN2KLK7 | |
| SCHEMBL15250789 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL15250780 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1BCL3LMNASMN1; SMN2 | |
| SCHEMBL9760978 | 0.81 | CD274 (0.64) | KMT2AALDH1A1LMNA | |
| SCHEMBL12459935 | 0.80 | CD274 (0.79) | ALDH1A1LMNASMN1; SMN2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | MAP3K2, MAP4K2, MAP3K12 | KMT2A 378/4885ALDH1A1 1651/4885BCL3 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.